The subject of the invention is the preventive use of genistein to prevent the loss of memory and cognitive abilities in humans resulting from the natural processes of brain aging.
This novel use of genistein significantly reduces the accumulation in the brain of harmful, insoluble protein aggregates and deposits, including beta-amyloid, which occurs during the process of physiological aging.
The solution involves the oral administration of genistein to prevent memory loss and cognitive decline in humans.
The effectiveness of genistein therapy is influenced by the fact that it crosses the blood-brain barrier. A key element of the developed technology is the correct dose of genistein, carefully selected so that the autophagy process is strong enough to remove toxic protein forms, yet mild enough to prevent the body from destroying healthy forms of proteins.
